Skip to main content
ABOS logo

ABOS · Acumen Pharmaceuticals, Inc.

Track ABOS — free
$0.19 -0.01 (-3.52%) At close · Nov 20
Market Cap
$13.49M
Shares
72.33M
Volume · Nov 20 2.71M Avg daily vol (3M) 2.7M

Price & Indicators

 

Key stats

Close
$0.19
Fri 20 Nov
Open
$0.19
Fri 20 Nov
Average volume, 30 days
5.3M
shares a session
Short interest
4.6M
6.3% of shares · 1.0 days to cover
Day range
$0.16$0.19
Open $0.19 Close $0.19
52-week closing range
$0.19$3.37
Close $0.19 94.5% under the high
Short volume, last session
54%
Last earnings
Oct 26, 2026
Latest filing
10-Q · Oct 26
Price history
Jul 2021 to Nov 2026

Up next

Jan 18, 2027 Est · unconfirmed · in 8 wks

Latest documents

2026
Nov 5
Current report 8-K Events of Nov 1
Debt repaid as workforce reduction begins

Acumen Pharmaceuticals, Inc. repaid and terminated its term loan for approximately $23.3 million on November 5, 2026. It is reducing 52 full-time employees, approximately 90% of its workforce, with approximately $7.75 million in cash restructuring costs.

Ended a material agreement, Exit or restructuring costs
4 source passages
On November 3, 2026, the Company provided notice of its intention to voluntarily prepay in full, using cash on hand, all outstanding obligations under the Loan Agreement in an aggregate amount of approximately $23.3 million (the “Payoff Amount”). On November 5, 2026, upon receipt by the Lender of the Payoff Amount, the Loan Agreement and certain other loan documents executed in connection therewith (other than those provisions that by their terms survive termination) were terminated, all commitments of the Lender thereunder were terminated, the Lender’s conversion right under the Loan Agreement terminated, and all liens and security interests securing the Company’s obligations under the Loan Agreement were released. In connection with these decisions, on November 1, 2026, the board of directors of the Company (the “Board”) approved certain steps to implement cash conservation measures, including a reduction of the Company’s workforce by 52 full-time employees, or approximately 90% of the Company’s current employee base (the “Restructuring”). As a result of the Restructuring, the Company estimates that it will incur approximately $7.75 million in costs resulting from cash expenditures consisting of one-time severance payments and related expenses. Open the document at this passage
Oct 30
Current report 8-K
Sabirnetug Phase 2 trial misses primary endpoint

Acumen Pharmaceuticals, Inc. said Phase 2 ALTITUDE-AD missed its primary endpoint at 18 months for both 35 mg/kg and 50 mg/kg doses, plans to cease sabirnetug development, implement cash conservation measures and explore strategic options.

Regulation FD disclosure, Other events
2 source passages
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that initial topline data from its Phase 2 ALTITUDE-AD clinical trial of sabirnetug (ACU193) in participants with early AD did not meet its primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months compared to placebo at either the 35 mg/kg or the 50 mg/kg dose. Based on the initial topline results, Acumen plans to cease development of sabirnetug, including the open-label extension portion of the ALTITUDE-AD trial, and to evaluate its strategic options, including its Enhanced Brain Delivery™ (EBD®) program. In the interim, the Company plans to take steps to implement cash conservation measures and explore strategic options to maximize shareholder value. Open the document at this passage
Oct 26
Registration statement S-3
Up to $500,000,000 Mixed Securities Shelf Registration Filed

Acumen Pharmaceuticals filed a shelf registration to sell up to $500,000,000 of any combination of common stock, preferred stock, debt securities and warrants, in one or more offerings. The last reported sale price was $1.98 per share on October 23, 2026.

Read from the first part of this long document
2 source passages
From time to time, we may offer and sell up to $500,000,000 of any combination of the securities described in this prospectus in one or more offerings. On October 23, 2026, the last reported sale price of our common stock was $1.98 per share. Open the document at this passage
Oct 26
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Going concern doubt as cash funds operations into early 2027

Acumen Pharmaceuticals reported a nine-month net loss of $78.8 million, down from $96.2 million, with cash and marketable securities of $78.6 million as of September 30, 2026. Management concluded there is substantial doubt about the company's ability to continue as a going concern, as cash is expected to fund operations only into early 2027.

Net loss $25.37M Diluted EPS -$0.35
Read from the MD&A section
4 source passages
Our net losses were $78.8 million and $96.2 million for the nine months ended September 30, 2026 and 2025, respectively. As of September 30, 2026, we had an accumulated deficit of $525.3 million and cash and cash equivalents and marketable securities of $78.6 million. The current balance of our cash and cash equivalents and marketable securities is expected to fund our operations into early 2027. Accordingly, management has concluded that substantial doubt exists regarding our ability to continue as a going concern. Open the document at this passage
Oct 26
Earnings call
Phase II Altitude AD readout for Soberna Tug due November

Acumen expects to report Phase II Altitude AD top-line results for Soberna Tug in November. Third-quarter net loss was $25.4 million, with approximately $79 million in cash and marketable securities.

3 source passages
So today, I'm pleased to confirm that we expect to announce these phase two results this November. We ended the third quarter with approximately $79 million in cash and marketable securities on our balance sheet, which is expected to support our current clinical and operational activities into early 2027. This led to a loss from operations of $25.8 million and a net loss of $25.4 million in the third quarter. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$103.96M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-652.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$52.33M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+19.4%
Year over year · more shares
Price change (1Y)
-88.0%
Trailing year
Short interest
6.3%
Latest settlement · 1.0 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 12, 2026
Q2 FY26

TL;DR. Acumen reported a narrower Q2 net loss and reduced R&D spending while advancing toward the late-2026 ALTITUDE-AD Phase 2 topline readout for sabirnetug in early Alzheimer's, and nominated two Enhanced Brain Delivery candidates with lead IND targeted for mid-2027; cash of $110.2M is stated to fund operations only into early 2027.

Bullish
  • + R&D expenses fell year-over-year in Q2 2026. new
  • + Two Enhanced Brain Delivery candidates were nominated, with lead IND targeted for mid-2027. new
Bearish
  • − Cash runway is stated to extend only into early 2027, ahead of the mid-2027 targeted EBD IND. new
  • − Company remains unprofitable with a Q2 2026 loss from operations of $32.6M. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −92%
below
Price vs 50-day avg −88%
below
RSI (14) 22
oversold
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −91%
trailing
6-month return −92%
trailing
YTD return −91%
this year
Relative strength −83%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +10 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.30% of shares out · ▲ +47.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
96 holders — near 3-yr high, broad support
Squeeze score 49
elevated · 0–100
Fundamentals
Fair
EPS growth −17%
Y/Y
Balance sheet $22.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 124%
annualized · 1-yr
Max drawdown −94%
past year
ATR 67.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Oct 26, 2026
30% slowing on the ibris · after 18 months of a placebo-controlled period 30%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−92% Bearish
Price vs 50-day avg
−88% Bearish
RSI (14)
22 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +10 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.30% of shares out · ▲ +47.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
96 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $3
vs 200-day avg -92% vs 50-day avg -88%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ABOS
Acumen Pharmaceuticals, Inc.
this stock
$13.49M -91.2% — — 6.3%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
96
% held
67.2%
Net QoQ
+729.8K sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
79
View
Short & Settlement
Short Interest Rising
Shares short
4.6M
Days to cover
1.0d
Change
+1.5M sh
View
Short Volume
Short vol %
54%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
23.1K
Value
$53.0K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
46.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-121.3M
EPS diluted
$-2.00
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 5, 2026
This year
25

Acumen Pharmaceuticals, Inc. repaid and terminated its term loan for approximately $23.3 million on November 5, 2026. It is reducing 52 full-time employees, approximately 90% of its workforce, with approximately $7.75 million in cash restructuring costs.

View
Proposed Sales
Value
$30.3K
Shares
13.0K
Filed
Jun 17, 2026
View
Earnings & Events
Webcasts
Last webcast
Oct 26, 2026
View
Investor Relations
Latest news
Acumen Pharmaceuticals Announces…
Published
Oct 30, 2026
View

Performance

5D 20D 120D MTD YTD
ABOS -12.9% -90.6% -92.1% -11.2% -91.2%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -4.3% -81.4% -83.0% -2.5% -92.3%
Key facts CIK 1576885 CUSIP 00509G209 13F (30d) 103 filings 89 filers Visit website Investor relations